IX Biopharma Awards $41M U.S. Government Contract for Wafermine Pain Therapy

February 12, 2026 — Biopharmaceutical company IX Biopharma (NASDAQ: IXBP) announced a $41 million contract with the U.S. government to advance its wafer-based therapy for chronic pain management. The funding supports Phase 3 trials and manufacturing scale-up. The therapy, delivered via a thin, sensor-based wafer, aims to provide targeted analgesia by modulating nerve activity. The company plans to report trial progress at the American Pain Society meeting in June 2026.